Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia.
出版信息
Gastroenterol Hepatol (N Y). 2006 Jan;2(1 Suppl 1):1-16.
Abstract
摘要
相似文献
1
Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia.乙肝和丙肝无应答者的治疗进展：亚太肝病研究学会第15届会议（2005年8月18 - 21日，印度尼西亚巴厘岛）专题研讨会报告
Gastroenterol Hepatol (N Y). 2006 Jan;2(1 Suppl 1):1-16.
2
Association between chronic hepatitis B virus infection and diabetes among Asian Americans and Pacific Islanders.亚裔美国人和太平洋岛民中慢性乙型肝炎病毒感染与糖尿病之间的关联。
Dig Liver Dis. 2007 Jun;39(6):549-56. doi: 10.1016/j.dld.2007.02.014. Epub 2007 Apr 9.
3
The declining prevalence of hepatitis B virus infection among Asian and Pacific Islander children.亚太岛民儿童中乙肝病毒感染率的下降
Asian Am Pac Isl J Health. 2001 Summer-Fall;9(2):162-78.
4
ASVAC2022 : 8 Asian Vaccine Conference.ASVAC2022：第 8 届亚洲疫苗大会。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165360. doi: 10.1080/21645515.2023.2165360. Epub 2023 Jan 19.
5
Report of the online meeting of the 7th Asian Conference on Environmental Mutagens (ACEM), China, November 5-6, 2022.第七届亚洲环境诱变剂学会会议（ACEM）线上会议报告，中国，2022年11月5日至6日。
Genes Environ. 2023 Feb 7;45(1):6. doi: 10.1186/s41021-023-00263-8.
6
China's efforts to shed its title of "Leader in liver disease".中国努力摆脱“肝病大国”的称号。
Drug Discov Ther. 2007 Oct;1(2):84-5.
7
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.亚太肝病学会肝癌共识建议。
Hepatol Int. 2010 Mar 18;4(2):439-74. doi: 10.1007/s12072-010-9165-7.
8
9
Report of the survey of hepatitis antigens in the Asian-Pacific region.
Ann Acad Med Singap. 1980 Apr;9(2):133-5.
10
Liver carcinoma prevention among Asian Pacific Islanders. Getting hepatitis B shots into arms.亚太岛民中的肝癌预防。将乙肝疫苗注射到手臂中。
Cancer. 2001 Jan 1;91(1 Suppl):252-6. doi: 10.1002/1097-0142(20010101)91:1+<252::aid-cncr14>3.0.co;2-y.
本文引用的文献
1
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.聚乙二醇干扰素α-2a、拉米夫定及两者联合治疗HBeAg阳性慢性乙型肝炎
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
2
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.胸腺肽α1对日本慢性乙型肝炎患者的疗效与安全性：一项随机临床试验的结果
J Viral Hepat. 2005 May;12(3):300-6. doi: 10.1111/j.1365-2893.2005.00633.x.
3
Immunology of hepatitis B virus and hepatitis C virus infection.乙型肝炎病毒和丙型肝炎病毒感染的免疫学
Nat Rev Immunol. 2005 Mar;5(3):215-29. doi: 10.1038/nri1573.
4
Viral hepatitis in minority America.美国少数族裔中的病毒性肝炎
J Clin Gastroenterol. 2005 Feb;39(2):144-51.
5
6
Thymalfasin: an immune system enhancer for the treatment of liver disease.胸腺法新：一种用于治疗肝病的免疫系统增强剂。
J Gastroenterol Hepatol. 2004 Dec;19(12):S69-72.
7
Thymalfasin for the treatment of chronic hepatitis B.胸腺法新治疗慢性乙型肝炎。
Expert Rev Anti Infect Ther. 2004 Feb;2(1):9-16. doi: 10.1586/14787210.2.1.9.
8
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.乙型肝炎病毒流行病学、疾病负担、治疗以及当前和新出现的预防控制措施。
J Viral Hepat. 2004 Mar;11(2):97-107. doi: 10.1046/j.1365-2893.2003.00487.x.
9
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.拉米夫定治疗慢性乙型肝炎患者的长期安全性。
Gastroenterology. 2003 Dec;125(6):1714-22. doi: 10.1053/j.gastro.2003.09.033.
10
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.阿德福韦酯治疗肝移植前后对拉米夫定耐药的乙型肝炎患者。
Hepatology. 2003 Dec;38(6):1419-27. doi: 10.1016/j.hep.2003.09.040.
Zotero 插件